Silymarin for the Prevention of Atrial Fibrillation After Cardiac Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

September 30, 2024

Conditions
Atrial Fibrillation New Onset
Interventions
DRUG

Silymarin

Subjects of the experimental group will receive silymarin (capsules containing 100 mg silymarin, expressed as silibinin) three days preoperatively. The dose they receive will be the recommended dose for the registered indications (400 mg daily, orally, divided into two doses).

Trial Locations (1)

21204

Institute of Cardiovascular Diseases of Vojvodina, Kamenitz

All Listed Sponsors
lead

University of Novi Sad

OTHER